Biohaven Ltd.
13.88USD
-0.8100 (-5.51%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on BHVN.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.16▲ | -$0.57 | 1 | 2 |
| Next quarter | -$0.13▲ | -$0.49 | 1 | 2 |
| Current year | -$1.3▲ | -$2.4 | 1 | 2 |
| Next year | -$1.74▲ | -$1.95 | 2 | 2 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.61 | -$0.78 | -0.17 (-27.6%) |
| 2026-03-31 | -$0.76 | -$0.69 | +0.07 (+9.7%) |
| 2025-12-31 | -$0.96 | -$0.9 | +0.06 (+5.8%) |
| 2025-09-30 | -$1.54 | -$1.47 | +0.07 (+4.8%) |
84 ratings from 18 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| RBC Capital | Maintained | Sector Perform | $19 $22 | Oct 23, 2026 |
| HC Wainwright & Co. | Reiterated | Neutral | $10 | Sep 10, 2026 |
| RBC Capital | Downgraded from Outperform | Sector Perform | $23 $19 | Sep 8, 2026 |
| Morgan Stanley | Maintained | Overweight | $18 $19 | Aug 12, 2026 |
| RBC Capital | Maintained | Outperform | $22 $23 | Aug 11, 2026 |
| B of A Securities | Downgraded from Neutral | Underperform | $12 $11 | Jun 29, 2026 |
| HC Wainwright & Co. | Reiterated | Neutral | $10 | May 26, 2026 |
| Morgan Stanley | Maintained | Overweight | $21 $18 | May 13, 2026 |
| RBC Capital | Maintained | Outperform | $23 $22 | May 5, 2026 |
| Citigroup | Maintained | Buy | $14 $17 | Apr 2, 2026 |
| TD Cowen | Maintained | Buy | $15 $30 | Mar 11, 2026 |
| HC Wainwright & Co. | Maintained | Neutral | $11 $10 | Mar 4, 2026 |
| RBC Capital | Maintained | Outperform | $22 $23 | Mar 3, 2026 |
| RBC Capital | Upgraded from Sector Perform | Outperform | $9 $22 | Jan 21, 2026 |
| Morgan Stanley | Maintained | Overweight | $26 $21 | Jan 6, 2026 |
| HC Wainwright & Co. | Reiterated | Neutral | $11 | Dec 26, 2025 |
| HC Wainwright & Co. | Downgraded from Buy | Neutral | $30 $11 | Dec 3, 2025 |
| UBS | Downgraded from Buy | Neutral | $26 $11 | Nov 26, 2025 |
| JP Morgan | Maintained | Overweight | $47 $15 | Nov 20, 2025 |
| Morgan Stanley | Maintained | Overweight | $54 $26 | Nov 18, 2025 |
| BTIG | Reiterated | Buy | $16 | Nov 18, 2025 |
| Citigroup | Maintained | Buy | $28 $14 | Nov 13, 2025 |
| Bernstein | Downgraded from Outperform | Market Perform | $34 $9 | Nov 6, 2025 |
| RBC Capital | Maintained | Sector Perform | $19 $9 | Nov 6, 2025 |
| BTIG | Maintained | Buy | $33 $16 | Nov 6, 2025 |
22 filings from 9 insiders · 0 buy / 0 sell over 6m
Officers and directors of BHVN, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Gentile KimberlyOfficer, SVP, Clinical Operations | GrantindirectStock Options (Right to buy) | 1.0k | — | — | Sep 15, 2026 |
| MEHTA KISHANDirector | Gift | 17.3k | — | — | Mar 17, 2026 |
| BUTEN MATTHEWChief Financial Officer | Other | 4.3k | — | — | Jan 5, 2026 |
| CLARK GEORGE C.Officer | Other | 2.5k | — | — | Jan 5, 2026 |
| CAR BRUCEOfficer | Other | 4.8k | — | — | Jan 5, 2026 |
| CORIC VLADIMIRChief Executive Officer | Other | 14.3k | — | — | Jan 5, 2026 |
| GENTILE KIMBERLY AOfficer | Other | 3.8k | — | — | Jan 5, 2026 |
| CLARK GEORGE C.Officer | Buyindirect | 17.0k | $8.52 | $145k | Nov 17, 2025 |
| CORIC VLADIMIRChief Executive Officer | Buyindirect | 666.7k | $7.50 | $5.00M | Nov 13, 2025 |
| BAILEY GREGORY HUGHDirector | Buy | 400.0k | $7.50 | $3.00M | Nov 13, 2025 |
| CHILDS JOHN WDirector | Buyindirect | 3.33M | $7.50 | $25.00M | Nov 13, 2025 |
| CHILDS JOHN WDirector | Buyindirect | 29.3k | $30.43 | $892k | Mar 4, 2025 |
| CHILDS JOHN WDirector | Buyindirect | 32.7k | $30.39 | $996k | Mar 4, 2025 |
| BUTEN MATTHEWChief Financial Officer | Other | 4.3k | — | — | Jan 3, 2025 |
| CLARK GEORGE C.Officer | Other | 2.5k | — | — | Jan 3, 2025 |
| CAR BRUCEOfficer | Other | 4.8k | — | — | Jan 3, 2025 |
| CORIC VLADIMIRChief Executive Officer | Other | 14.3k | — | — | Jan 3, 2025 |
| GENTILE KIMBERLY AOfficer | Other | 3.8k | — | — | Jan 3, 2025 |
| CHILDS JOHN WDirector | Buyindirect | 29.0k | $35.94 | $1.04M | Dec 30, 2024 |
| CORIC VLADIMIRChief Executive Officer | Buyindirect | 21.1k | $47.50 | $1000k | Oct 2, 2024 |
No analyst notes on BHVN yet.
Analyst Ratings
15 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 3 | 9 | 4 | 0 | 1 | Buy2.24 |
| 1 mo ago | 3 | 9 | 4 | 0 | 1 | Buy2.24 |
| 2 mo ago | 4 | 9 | 3 | 0 | 1 | Buy2.12 |
| 3 mo ago | 4 | 9 | 3 | 0 | 1 | Buy2.12 |
Members whose judged calls on BHVN have played out most reliably.
No settled calls on BHVN yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice